Rational design of novel diaryl ether-linked benzimidazole derivatives as potent and selective BACE1 inhibitors

Due to the large size and high flexibility of the catalytic active site of BACE1 enzyme, the development of nonpeptide inhibitors with optimal pharmacological properties is still highly demanding. In this work, we have discovered 2-aminobenzimidazole-containg ether scaffolds having potent and select...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2024-02, Vol.698, p.149538, Article 149538
Main Authors: Quang De, Tran, Nguyen, Cuong Quoc, Le Dang, Quang, Nguyen Thi, Nhu Y., Trong Tuan, Nguyen, Hoon Suh, Dong, Chu, Jeonghyun, Bepary, Sukumar, Lee, Ge Hyeong, Kang, Nam Sook, Cho, Heeyeong, Park, Woo Kyu, Lim, Hee-Jong
Format: Article
Language:English
Subjects:
Alzheimer Disease
Alzheimer's disease
Amyloid Precursor Protein Secretases - antagonists & inhibitors
Aspartic Acid Endopeptidases - antagonists & inhibitors
BACE1
Benzimidazole
Benzimidazoles - pharmacology
Drug Design
Ethers
Humans
Molecular docking
Molecular Docking Simulation
Non-peptide
β-secretase
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to the large size and high flexibility of the catalytic active site of BACE1 enzyme, the development of nonpeptide inhibitors with optimal pharmacological properties is still highly demanding. In this work, we have discovered 2-aminobenzimidazole-containg ether scaffolds having potent and selective inhibitory potentials against BACE1 enzyme. We have synthesized novel 29 compounds and optimization of aryl linker region resulted in highly potent BACE1 inhibitory activities with EC50 values of 0.05–2.71 μM. The aryloxy-phenyl analogs 20j showed the EC50 value as low as 0.07 μM in the enzyme assay, whereas, the benzyloxyphenyl dervative 24b was comparatively less effective in the enzyme assay. But interestingly the latter was more effective in the cell assay (EC50 value 1.2 μM). While comparing synthesized derivatives in the cell assay using PC12-APPSW cell, compound 27f appeared as the most potent BACE1 inhibitor having EC50 value 0.7 μM. This scaffold also showed high selectivity over BACE2 enzyme and cathepsin D. Furthermore, the research findings were bolstered through the incorporation of molecular docking, molecular dynamics, and DFT studies. We firmly believe that these discoveries will pave the way for the development of a novel class of small-molecule selective BACE1 inhibitors. [Display omitted] •29 Novel diaryl ether-benzimidazole derivatives exhibit potent BACE1 inhibition.•Some compounds showed the EC50 value as low as 0.07 μM in the enzyme assay.•Compound 27f most potent BACE1 inhibitor having EC50 value 0.7 μM in cell assay.•Some derivatives showed SI greater than 15 in BACE2 and cathepsin D inhibitory assays.•The interactions of lead compounds with BACE1 were elucidated by in silico models.
ISSN:0006-291X
1090-2104
1090-2104
DOI:10.1016/j.bbrc.2024.149538